What clinical trials are usually required for a biosimilar?
Biosimilar developers generally have to show that their product is “highly similar” to the reference biologic in terms of structure and function, and that there are no clinically meaningful differences in safety or effectiveness. The clinical evidence typically comes from one or more clinical studies designed to confirm similarity in pharmacokinetics (PK), immunogenicity, and/or clinical response, rather than repeating the full set of original approval trials done for the reference product.
How do regulators expect the trials to be designed?
Most biosimilar pathways rely on a stepwise approach: extensive analytical and nonclinical comparison first, then targeted clinical studies to address remaining uncertainties. Common themes regulators look for in biosimilar clinical programs include:
- Matching the reference product’s target population and dosing approach as closely as practical.
- Using endpoints that can detect differences in exposure, response, and immune reactions.
- Assessing immunogenicity with assays that are capable of characterizing antibodies and their impact (for example, whether antibodies affect PK/PD or clinical response).
Which clinical endpoints are most commonly used?
Depending on the mechanism of action and what is already confirmed through lab/functional studies, the clinical component often focuses on:
- Pharmacokinetics (exposure measures) to show similar absorption/distribution and overall drug exposure.
- Pharmacodynamics or surrogate markers, when relevant to confirm functional similarity.
- Immunogenicity (antidrug antibodies and related effects).
- Clinical effectiveness and/or safety outcomes when needed to support similarity or when there are residual risks that cannot be resolved without clinical data.
How many trials are required—does it have to be one big study?
Requirements vary by product class, complexity, and what the totality of evidence shows from analytical, functional, and nonclinical comparisons. Some biosimilar applications rely on a focused clinical study with sufficient sensitivity to demonstrate similarity in PK/exposure and immunogenicity, while others may use additional or confirmatory clinical evidence. The goal is not to replicate the reference product’s entire clinical development program, but to provide enough clinical data to rule out clinically meaningful differences.
Do biosimilars need new safety trials?
Biosimilar submissions still require safety evidence, but the expectation is usually “similar safety” supported by the totality of evidence. Safety assessment commonly includes adverse events and immunogenicity outcomes in the biosimilar clinical studies. Longer-term safety follow-up depends on the product and the clinical development plan, but biosimilar programs are not automatically expected to run a brand-new set of large, long-term outcomes trials unless the evidence gap cannot be closed with other comparisons.
What about immunogenicity—why is it emphasized?
Immunogenicity is a central reason biosimilar clinical trials can’t be purely analytical. Differences in manufacturing or formulation can affect how the immune system recognizes the biologic, which can change efficacy and safety. As a result, immunogenicity is frequently measured in the clinical study and interpreted alongside PK and, where applicable, clinical response.
Can extrapolation reduce or change what clinical trials are needed?
Often yes. If a biosimilar demonstrates similarity in one indication and the sponsor can justify that the mechanism, receptor/target, and safety/PK relationships are comparable across indications, regulators may allow extrapolation to additional approved uses without running separate clinical trials in each indication. Extrapolation still depends on the biosimilar’s total evidence package and the regulatory justification.
Do requirements differ for interchangeable biosimilars?
If a product aims for “interchangeability” (a stricter standard than biosimilarity in some jurisdictions), regulators may expect additional evidence addressing switching and its impact on safety and immunogenicity. The exact evidence expectations depend on the regulatory framework and the claim being sought.
How are requirements handled in the U.S. versus the EU?
Broadly, both the U.S. and EU biosimilar frameworks rely on a scientific, totality-of-evidence approach that combines analytical, nonclinical, and clinical studies, but the details of how evidence is packaged and what claims can be made (including extrapolation and interchangeability) differ by jurisdiction. If you tell me which country/region you mean (e.g., U.S., EU, UK), I can tailor the trial expectations to that framework.
Sources
I don’t have the specific provided source materials in this chat to cite the exact regulatory text or guidance for biosimilar clinical trial requirements. If you share the reference guidance/documents you want used (or the jurisdiction—FDA vs EMA/EC), I’ll produce a cited answer that matches them.